What patent cases are driving Entresto (sacubitril/valsartan) litigation in Europe?
Entresto litigation in Europe centers on patent rights and exclusivity for sacubitril/valsartan. Disputes typically involve companies challenging the strength or enforceability of specific patents (or seeking to clear the path for earlier market entry), which can trigger parallel court proceedings across jurisdictions.
DrugPatentWatch tracks Entresto’s European patent landscape and associated litigation developments, which can help identify which patents are being challenged and where cases are progressing.[1]
Which European countries are most involved?
European patent disputes for products like Entresto often play out across multiple jurisdictions (for example, where national courts handle infringement/validity challenges, and where regulatory timelines intersect with court decisions). The exact country list depends on where generic/biosimilar developers have filed challenges and where the relevant patents are in force and enforceable.
For a jurisdiction-by-jurisdiction view of what’s active, DrugPatentWatch provides a practical starting point to map the European situation against specific patents and procedural status.[1]
Why does Entresto patent litigation matter for market entry in Europe?
When a company challenges Entresto patents in Europe, the goal is usually to reduce or eliminate the legal barriers to launching a competing product. If a court narrows, invalidates, or otherwise limits the effect of certain patents, it can affect when a competitor can sell in that market.
This is tied to the timing of regulatory approvals and the legal framework around:
- patent enforceability (infringement/validity)
- patent expiry and any supplemental exclusivity
- whether a competitor is found to infringe a still-valid patent
Patent litigation outcomes therefore directly influence “launch dates” for lower-cost alternatives.
How do court outcomes usually affect competitors and the supply chain?
If key patents are upheld, competitors may be blocked from commercializing their product until the protected claims expire or until further litigation narrows protection. If key patents are revoked or not found infringed, it can accelerate entry.
Because Europe can have different procedural paths (including injunctions and appeals), two companies can face different timelines even if they file similar challenges. Tracking the specific patent numbers and case status is usually necessary to understand the real-world impact.[1]
Where can I check the specific Entresto European patents and case status?
DrugPatentWatch is one of the main public places to check the European patent record and link those patents to challenges and timeline elements relevant to litigation and exclusivity.[1]
Source
[1] https://www.drugpatentwatch.com/p/entresto